BridgeBio Pharma, Inc.
General ticker "BBIO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $7.6B (TTM average)
BridgeBio Pharma, Inc. follows the US Stock Market performance with the rate: 61.1%.
Estimated limits based on current volatility of 1.6%: low 72.00$, high 74.32$
Factors to consider:
- Total employees count: 730 as of 2024
- Top business risk factors: Product recalls, Single supplier dependency, Strategic risks and growth management, Regulatory and compliance, Geopolitical risks
- Current price 138.2% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [12.09$, 31.38$]
- 2025-12-31 to 2026-12-31 estimated range: [8.28$, 22.35$]
Financial Metrics affecting the BBIO estimates:
- Negative: with PPE of -8.4 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -10.23 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 1.95 <= 3.41
- Negative: Shareholder equity ratio, % of -159.67 <= 18.93
Short-term BBIO quotes
Long-term BBIO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $77.65MM | $9.30MM | $221.90MM |
| Operating Expenses | $589.85MM | $616.67MM | $814.88MM |
| Operating Income | $-512.20MM | $-607.37MM | $-592.97MM |
| Non-Operating Income | $27.55MM | $-45.88MM | $50.78MM |
| Interest Expense | $80.44MM | $81.29MM | $99.29MM |
| R&D Expense | $399.46MM | $455.71MM | $506.46MM |
| Income(Loss) | $-484.65MM | $-653.25MM | $-542.19MM |
| Taxes | $0.00MM | $0.00MM | $1.15MM |
| Profit(Loss)* | $-481.18MM | $-643.20MM | $-535.76MM |
| Stockholders Equity | $-1,254.62MM | $-1,354.26MM | $-1,467.90MM |
| Assets | $623.04MM | $546.38MM | $919.34MM |
| Operating Cash Flow | $-419.49MM | $-527.72MM | $-520.73MM |
| Capital expenditure | $6.32MM | $1.31MM | $0.93MM |
| Investing Cash Flow | $453.15MM | $54.03MM | $60.78MM |
| Financing Cash Flow | $-13.13MM | $451.54MM | $748.46MM |
| Earnings Per Share** | $-3.26 | $-3.95 | $-2.88 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.